Discover Viatris' Q3 2025 earnings highlights: strengthened financials, raised guidance, pipeline progress, and strategic cost savings.

A popular muscle relaxer made in New Jersey is being recalled due to a label swap, according to the FDA. The product was ...

Read more on Prohibited Substance - St John Gray Winner Disqualified on Sporting Post, bringing you the latest in Horse Racing News, Previews and Reviews.

Unichem Pharmaceuticals has recalled one lot of a muscle relaxer because the pills in the bottle might not be the muscle relaxer on the label. The East Brunswick, New Jersey, company’s FDA-posted ...

The U.S. subsidiary of India’s Unichem Pharmaceuticals is voluntarily recalling one lot of the muscle relaxant cyclobenzaprine hydrochloride after a labeling snafu. The lot being recalled is ...

Unichem Laboratories subsidiary Unichem Pharmaceuticals (USA) Inc. is recalling one lot of muscle relaxant drug Cyclobenzaprine Hydrochloride Tablets USP 10 mg to the consumer level in the U.S. in the ...

A nationwide recall has been initiated by Unichem Pharmaceuticals due to a significant pill mix-up. Certain bottles of Cyclobenzaprine Hydrochloride Tablets, intended as a muscle relaxant, were ...

A pharmaceutical company is recalling one of its products after discovering that the pill bottle could be filled with the wrong medication. According to the Food and Drug Administration (FDA), Unichem ...

Providing an over-the-counter pain relief product for goat will be complex and costly and more work is needed to determine the best way to do it. National sheep and wool writer for ACM's agricultural ...

PITTSBURGH, Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of ...

In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain ...

A reduction in opioid usage over the entire treatment period was observed in patients treated with MR-107A-02 vs placebo. Topline data were announced from two phase 3 studies evaluating MR-107A-02 for ...